Mapping molecular diversity shows significant implications for understanding prostate cancer progression.
Key evidence reveals distinct biomarkers identified through multiplex immunohistochemistry and RNA in situ hybridization methods.
Assessment using advanced imaging techniques highlights unique molecular features across prostate cancer samples.
Findings suggest tailored therapeutic strategies may be developed based on molecular profiles in prostate cancer.
Abstract
The cover image is based on the article Mapping Molecular Diversity in Prostate Cancer with a combined Multiplex IHS and RNA-ISH by Nallasivam Palanisamy et al., https://doi.org/10.1002/pros.70108